IL-1 inhibitors are also promising in two highly prevalent inflammatory diseases, encountered as co-morbidities in patients with rheumatic diseases, namely arteriosclerosis and type 2 diabetes. The gene discussed is IL1B; the disease is type 2 diabetes mellitus.